Investigation of the prognostic significance of c-kit and c-erb-b2 expression in osteosarcoma, ewing sarcoma, and rhabdomyosarcoma and comparison with clinical parameters

• Gulay Aydogdu ^[1] ; Bilge Bilgic ^[2] ; Kumru Kıroglu ^[3]
  1. [1] Dicle University

     Dicle University

     Turquía

     
  2. [2] Istanbul University

     Istanbul University

     Turquía

     
  3. [3] Department of Pathology, Kırklareli Education and Research Hospital, KIRKLARELİ, TURKEY

  Mostrar afiliaciones +
• Localización: Academic Journal of Health Sciences: Medicina Balear, ISSN-e 2255-0560, Vol. 38, Nº. 5, 2023, págs. 77-83
• Idioma: inglés
• DOI: 10.3306/AJHS.2023.38.05.77
• Títulos paralelos:
  • Investigación de la importancia pronóstica de la expresión de c-kit y c-erb-b2 en osteosarcoma, sarcoma de ewing y rabdomiosarcoma y comparación con parámetros clínicos
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Objetivo: En el presente estudio, se evaluaron las funciones de guía de tratamiento y pronóstico de la oncoproteína c-erb-B2 y el receptor de tirosina quinasa c-kit en osteosarcoma (OS), sarcoma de Ewing (ES) y rabdomiosarcoma (RMS).

    Materiales y métodos: Con 25 casos de cada grupo, se investigó inmunohistoquímicamente la expresión de c-kit y c-erb-B2 en un total de 75 casos.

    Resultados: Se encontró que tinción para c-kit fue positiva en 15(60%) de RMS, 11 de casos de OS (44%) y 11 de los casos de ES (44%). La tinción de C-erbB-2 fue positiva en 7 casos de RMS (8%) y negativa en todos los casos de OS y ES. Se aplicó el método SISH a seis casos de RMS positivos para c-erb-B2, la amplificación del gen HER2 (que codifica c-erb-B2) se detectó en caso. Se determinó que expresión de c-kit en OS se asoció significativamente con supervivencia (p<0,05), podría considerarse como un parámetro de mal pronóstico.

    Conclusión: se concluyó que la expresión de c-kit se puede utilizar como un parámetro de mal pronóstico para OS y que la terapia dirigida a c-kit puede ser una opción de tratamiento alternativa.

  • English

    Objective: In the present study, the prognostic and treatment-guiding roles of the c-erb-B2 oncoprotein and tyrosine kinase receptor c-kit in osteosarcoma (OS), Ewing sarcoma (ES), and rhabdomyosarcoma (RMS) were evaluated.

    Materials and methods: With 25 cases from each group, c-kit and c-erb-B2 expression were investigated immunohistochemically in a total of 75 cases.

    Results: Staining for c-kit was found to be positive in 15 (60%) of the RMS, 11 of the OS (44%), and 11 of the ES cases (44%).

    C-erbB-2 staining was positive in 7 RMS cases (8%) and negative in all cases of OS and ES.The SISH method was applied to six c-erb-B2 positive RMS cases, and amplification of the HER2 gene (encoding c-erb-B2) was detected in one case. It was determined that c-kit expression in OS was significantly associated with survival (p<0.05) and could be considered as a poor prognostic parameter. In contrast,c-kit expression had no prognostic significance in ES and RMS. In the RMS group, there was no relationship between c-erb-B2 positivity and prognosis.

    Conclusion: It was concluded that c-kit expression can be used as a poor prognostic parameter for OS and therapy targeting c-kit may be an alternative treatment option.

• Referencias bibliográficas
  • Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatol Ther. 2016 Dec;3(2):221-43
  • Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev...
  • Shabani P, Izadpanah S, Aghebati-Maleki A, Baghbani E, Baghbanzadeh A, Fotouhi A, et al. Role of miR-142 in the pathogenesis of osteosarcoma...
  • Lokuhetty D, White VA, Cree IA. ed. Undifferentiated small round cell sarcomas of bone and soft tissue, Ewing sarcoma. In: WHO Classification...
  • Scurr M, Judson I. How to treat the Ewing’s family of sarcomas in adult patients. Oncologist. 2006 Jan;11(1):65-72.
  • Weiss SW, Goldblum JR. Rhabdomyosarcoma. In: Enzinger and Weiss’s Soft Tissue Tumors, 6th ed., China: Elsevier Saunders;2014;601-38.
  • Entz-Werlé N, Marcellin L, Gaub MP, Guerin E, Schneider A, Berard-Marec P, et al. Prognostic significance of allelic imbalance at the c-kit gene...
  • Chaiyawat P, Klangjorhor J, Settakorn J, Champattanachai V, Phanphaisarn A, Teeyakasem P, et al. Activation Status of Receptor Tyrosine Kinases...
  • Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid...
  • Willmore-Payne C, Holden JA, Zhou H, Gupta D, Hirschowitz S, Wittwer CT, et al. Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence...
  • Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, et al. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft...
  • Wang K, Liu J, Duan Y, Wu J, Dongye S, Wang Y, et al. C-erbB-2 expression is related with pathological progression of gastric cancer: results...
  • Schaller G, Evers K, Papadopoulos S, Ebert A, Bühler H. Current use of HER2 tests. Ann Oncol. 2001;12 Suppl 1:S97-100.
  • Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue...
  • Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012 Oct;92(4):1619-49.
  • Sabah M, Leader M, Kay E. The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem...
  • Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol. 2004...
  • Miiji LN, Petrilli AS, Di Cesare S, Odashiro AN, Burnier MN Jr, de Toledo SR, et al. C-kit expression in human osteosarcoma and in vitro assays....
  • Saeter G, Oliveira J, Bergh J; ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and followup of...
  • Sulzbacher I, Birner P, Toma C, Wick N, Mazal PR. Expression of c-kit in human osteosarcoma and its relevance as a prognostic marker. J Clin...
  • Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, et al. Overexpression of the HER-2 oncogene does not play...
  • Do I, Araujo ES, Kalil RK, Bacchini P, Bertoni F, Unni KK, et al. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing...
  • Landuzzi L, Strippoli P, De Giovanni C, Nicoletti G, Rossi I, Tonelli R, et al. Production of stem cell factor and expression of c-kit in...
  • Armistead PM, Salganick J, Roh JS, Steinert DM, Patel S, Munsell M, et al. Expression of receptor tyrosine kinases and apoptotic molecules...
  • Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma....
  • Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, et al. Prognostic and therapeutic relevance of HER2 expression in...
  • Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma....
  • Ganti R, Skapek SX, Zhang J, Fuller CE, Wu J, Billups CA, et al. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal...